Risk factors for occurrence and 30-day mortality for carbapenem-resistant Acinetobacter baumannii bacteremia in an intensive care unit
- PMID: 22876063
- PMCID: PMC3410244
- DOI: 10.3346/jkms.2012.27.8.939
Risk factors for occurrence and 30-day mortality for carbapenem-resistant Acinetobacter baumannii bacteremia in an intensive care unit
Abstract
To assess the risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) bacteremia and for 30-day mortality in patients with CRAB bacteremia in the intensive care unit (ICU), we conducted a retrospective study in the ICU at Severance Hospital in Korea from January 2008 to December 2009. Patients who acquired CRAB bacteremia in the ICU were enrolled as the case group and patients whose specimens of blood culture, sputum/endotracheal aspirate and urine revealed no AB were enrolled as controls. The case group comprised 106 patients and 205 patients were included as controls. Risk factors independently associated with CRAB bacteremia included prior chemotherapy or radiotherapy treatment (Odds ratio [OR], 3.6; P = 0.003), recent central venous catheter insertion (OR, 5.7; P < 0.001) or abdominal drainage insertion (OR, 21.9; P = 0.004), the number of antibiotics treated with (OR, 1.3; P = 0.016), and respiratory failure in the ICU (OR, 2.5; P = 0.035). The 30-day mortality was 79.8%. Renal failure during ICU stay was independently associated with 30-day mortality (OR, 3.7; P = 0.047). It is important to minimize invasive procedures, and to restrict excessive use of antibiotics, especially in immunocompromised patients, in order to prevent the development of CRAB bacteremia. Greater concern for CRAB bacteremia patients is needed when renal failure develops during ICU stay.
Keywords: Acinetobacter baumannii; Bacteremia; Drug Resistance, Multiple; Intensive Care Units; Mortality; Risk Factors.
Figures



Similar articles
-
Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes.Infection. 2010 Jun;38(3):173-80. doi: 10.1007/s15010-010-0008-1. Epub 2010 Mar 12. Infection. 2010. PMID: 20224962
-
Prospective multi-center evaluation on risk factors, clinical characteristics and outcomes due to carbapenem resistance in Acinetobacter baumannii complex bacteraemia: experience from the Chinese Antimicrobial Resistance Surveillance of Nosocomial Infections (CARES) Network.J Med Microbiol. 2020 Jul;69(7):949-959. doi: 10.1099/jmm.0.001222. J Med Microbiol. 2020. PMID: 32584215
-
Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.J Microbiol Immunol Infect. 2016 Dec;49(6):934-940. doi: 10.1016/j.jmii.2014.10.006. Epub 2014 Nov 11. J Microbiol Immunol Infect. 2016. PMID: 25553994
-
Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis.Am J Infect Control. 2019 Sep;47(9):1140-1145. doi: 10.1016/j.ajic.2019.03.003. Epub 2019 Apr 17. Am J Infect Control. 2019. PMID: 31003750
-
The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis.Emerg Microbes Infect. 2019;8(1):1747-1759. doi: 10.1080/22221751.2019.1698273. Emerg Microbes Infect. 2019. PMID: 31805829 Free PMC article.
Cited by
-
Prognostic Risk Factors of Carbapenem-Resistant Gram-Negative Bacteria Bloodstream Infection in Immunosuppressed Patients: A 7-Year Retrospective Cohort Study.Infect Drug Resist. 2022 Nov 2;15:6451-6462. doi: 10.2147/IDR.S386342. eCollection 2022. Infect Drug Resist. 2022. PMID: 36349216 Free PMC article.
-
Risk Factors and Molecular Features of Sequence Type (ST) 131 Extended-spectrum β-Lactamase-producing Escherichia coli in Community-onset Bacteremia.Sci Rep. 2017 Nov 7;7(1):14640. doi: 10.1038/s41598-017-14621-4. Sci Rep. 2017. PMID: 29116143 Free PMC article.
-
Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis.Indian J Pharmacol. 2015 Jan-Feb;47(1):95-100. doi: 10.4103/0253-7613.150383. Indian J Pharmacol. 2015. PMID: 25821319 Free PMC article.
-
Dynamic monitoring of neutrophil/lymphocyte ratio, APACHE II score, and SOFA score predict prognosis and drug resistance in patients with Acinetobacter baumannii-calcoaceticus complex bloodstream infection: a single-center retrospective study.Front Microbiol. 2024 Jan 23;15:1296059. doi: 10.3389/fmicb.2024.1296059. eCollection 2024. Front Microbiol. 2024. PMID: 38322313 Free PMC article.
-
Nosocomial, Healthcare-Associated, and Community-Acquired Acinetobacter baumannii in China: Clinical Characteristics, Antimicrobial Resistance Patterns and Risk Factors Associated with Carbapenem Resistance.Infect Drug Resist. 2024 Sep 19;17:4089-4099. doi: 10.2147/IDR.S469244. eCollection 2024. Infect Drug Resist. 2024. PMID: 39319039 Free PMC article.
References
-
- Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med. 2008;358:1271–1281. - PubMed
-
- Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect. 2005;11:868–873. - PubMed
-
- Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 2008;13:19045. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical